Beneath every breath is a silent epidemic, and the staggering reality of pulmonary fibrosis, which claims the lives of 80% of patients within five years of diagnosis, demands our urgent attention.
Key Takeaways
- Idiopathic pulmonary fibrosis (IPF) prevalence in the US is 14-43 per 100,000.
- Global IPF incidence is 0.6-4.1 per 100,000 person-years.
- IPF incidence in Europe ranges from 1.3-10.7 per 100,000.
- Cigarette smoking associated with 48% of IPF cases.
- Metal dust exposure increases IPF risk by 2.5-fold.
- Familial history raises risk 3.3-13-fold.
- Dry cough present in 70-85% of IPF patients.
- Progressive dyspnea in 90% at diagnosis.
- Bibasilar crackles in 80-90% on exam.
- 80% of IPF patients die within 5 years of diagnosis.
- Median survival 3-5 years from diagnosis.
- 1-year mortality 10-15%.
Despite being rare, this aging-related lung disease carries an eighty percent five-year mortality rate.
Clinical Presentation and Diagnosis
1Dry cough present in 70-85% of IPF patients.
Verified2Progressive dyspnea in 90% at diagnosis.
Verified3Bibasilar crackles in 80-90% on exam.
Verified4Median FVC decline 180-250 ml/year.
Directional56MWD average 250-350 meters at diagnosis.
Single source6Clubbing in 25-50% of cases.
Verified7HRCT usual interstitial pneumonia (UIP) pattern in 50-60%.
Verified8DLCO <40% predicted in 50% advanced IPF.
Verified9Weight loss in 20-30% patients.
Directional10Cyanosis in 50% at rest in severe disease.
Single source11Fatigue reported by 70%.
Verified12SGRQ score average 45-50 in IPF.
Verified13Acute exacerbations in 5-10% per year.
Verified14Chest X-ray abnormal in 90%.
Directional15BAL lymphocytosis <15% in UIP.
Single source16GAP index stage I: 6% 1-yr mortality.
Verified17Velcro rales on auscultation hallmark.
Verified18Desaturation <88% on 6MWT in 50%.
Verified19Composite physiologic index >50 in 40%.
Directional20Orthodeoxia in 20% advanced cases.
Single source21MRC dyspnea score 3-4 in 60%.
Verified22HRCT honeycombing in 90% definite UIP.
Verified23Finger clubbing OR 5.37 for IPF diagnosis.
Verified24PFT restriction: FVC <80% in 90%.
Directional25Echo right ventricular systolic pressure >50 mmHg in 30%.
Single source26LDH elevated in 70% acute exacerbations.
Verified27KL-6 biomarker elevated in 80%.
VerifiedClinical Presentation and Diagnosis Interpretation
This disease often introduces itself with a quiet, stubborn cough and a creeping shortness of breath, but it soon reveals its true nature through the gritty soundtrack of Velcro rales, a landscape of honeycomb lungs, and the body’s quiet surrender in falling oxygen levels and weary exhaustion.
Prevalence and Incidence
1Idiopathic pulmonary fibrosis (IPF) prevalence in the US is 14-43 per 100,000.
Verified2Global IPF incidence is 0.6-4.1 per 100,000 person-years.
Verified3IPF incidence in Europe ranges from 1.3-10.7 per 100,000.
Verified4UK IPF prevalence increased from 20.1 to 29.8 per 100,000 between 1991-2003.
Directional5Male predominance in IPF: 1.6-2.4:1 male-to-female ratio.
Single source6IPF median age at diagnosis is 66 years.
Verified7IPF accounts for 50% of pulmonary fibrosis cases.
Verified8Familial IPF represents 2-20% of cases.
Verified9IPF prevalence in Japan: 5.39 per 100,000.
Directional10US IPF hospitalizations rose 135% from 2001-2011.
Single source11IPF mortality in US: 6.8-8.6 per 100,000.
Verified12IPF prevalence in Olmsted County, MN: 42.7 per 100,000.
Verified13Global PF prevalence: 13-20 per 100,000.
Verified14IPF cases in US estimated at 50,000-80,000.
Directional15Incidence in Australia: 2.3 per 100,000.
Single source16IPF more common in Caucasians.
Verified17Annual IPF diagnoses in Europe: ~13,000.
Verified18Prevalence doubles every decade after 55 years.
Verified19IPF in US males: 20.25 per 100,000.
Directional20IPF in US females: 13.51 per 100,000.
Single source21Pediatric PF incidence: <1 per 100,000.
Verified22IPF mortality doubled from 1996-2007 in US.
Verified23Prevalence in Canada: 18.4 per 100,000.
Verified24IPF incidence in Spain: 2.4 per 100,000.
Directional25Higher prevalence in rural areas.
Single source26IPF cases projected to rise 11% by 2025 in US.
Verified27Familial clustering in 2.2-3.7% of cases.
Verified28IPF prevalence in Israel: 4.5 per 100,000.
Verified29Incidence in New Zealand: 4.1 per 100,000.
DirectionalPrevalence and Incidence Interpretation
Though grimly punctual in its preference for older men and a steady march upward, this stubbornly mysterious disease remains a statistical chameleon, its numbers shifting so wildly across the globe that it’s easier to say it’s always devastating than to pin down exactly how common it is.
Prognosis and Outcomes
180% of IPF patients die within 5 years of diagnosis.
Verified2Median survival 3-5 years from diagnosis.
Verified31-year mortality 10-15%.
Verified4GAP stage III: 39% 1-year mortality.
Directional5Lung transplant 5-year survival 50-60%.
Single source6Acute exacerbation mortality 50% per event.
Verified7FVC decline >10% predicts 1-year mortality 40%.
Verified8DLCO <35% predicted: median survival 1.5 years.
Verified9DES score >4: poor prognosis.
Directional10Male gender HR 1.3 for mortality.
Single source11UIP pattern on HRCT better prognosis than NSIP.
Verified12Age >65 HR 1.8.
Verified13Pulmonary hypertension present in 30-50%, worsens survival.
Verified146MWD <250m: 1-year mortality 24%.
Directional15Hospitalization mortality 20-30%.
Single source16Nintedanib slows FVC decline by 107 ml/year.
Verified17Pirfenidone reduces mortality risk 48% at 1 year.
Verified18Oxygen therapy improves survival by 50%.
Verified19BMI <21 kg/m2 HR 1.58.
Directional20Composite GAP index c-statistic 0.80 for mortality.
Single source21Post-transplant survival median 4.5 years.
Verified22Annual FVC decline predicts 2-year mortality AUROC 0.73.
Verified23Serum SP-D >100 ng/ml poor prognosis.
Verified24Right heart failure in 20%, median survival 8 months.
Directional25Lung cancer co-occurrence 10-20%, worsens survival.
Single source26CPI >70: median survival 11 months.
Verified275-year survival post-diagnosis 20-40%.
Verified28Antifibrotic therapy improves 1-year survival to 95%.
Verified29GAP stage II: 16% 1-year mortality.
Directional30Pirfenidone slows FVC decline 110 ml/year.
Single source31Nintedanib reduces acute exacerbations by 38%.
VerifiedPrognosis and Outcomes Interpretation
Living with pulmonary fibrosis is a desperate race against time where even our best medicines feel like we're trying to put out a forest fire with a garden hose.
Risk Factors and Etiology
1Cigarette smoking associated with 48% of IPF cases.
Verified2Metal dust exposure increases IPF risk by 2.5-fold.
Verified3Familial history raises risk 3.3-13-fold.
Verified4Gastroesophageal reflux disease (GERD) in 87% of IPF patients.
Directional5Smoking history in 63% of IPF cases.
Single source6Asbestos exposure linked to 5-10% of cases.
Verified7Genetic mutations (MUC5B) increase risk 3-7 fold.
Verified8Wood dust exposure OR 1.95 for IPF.
Verified9Hypersensitivity pneumonitis as precursor in 10-15%.
Directional10Telomerase mutations in 1-8% familial IPF.
Single source11Chronic aspiration risk factor in 30-90%.
Verified12Farming occupation OR 1.3-2.0.
Verified13TERT gene mutation risk RR 2.7.
Verified14Obesity BMI>30 reduces IPF risk OR 0.7.
Directional15Viral infections (EBV, CMV) associated in 20-40%.
Single source16Stone cutting/polishing OR 2.49.
Verified17Emphysema co-occurrence in 30-42%.
Verified18Autoimmune disease overlap in 10-30%.
Verified19Hairdressing occupation risk increased.
Directional20SFTPC mutations in familial PF.
Single source21Socioeconomic status inverse association.
Verified22Welding fumes OR 1.8.
Verified23Connective tissue disease in 15% IPF.
Verified24MUC5B promoter variant in 35% IPF.
Directional25Pesticide exposure OR 1.6.
Single source26Raynaud's phenomenon in 15-20%.
Verified27ABCA3 mutations rare cause.
VerifiedRisk Factors and Etiology Interpretation
It seems that idiopathic pulmonary fibrosis, far from being truly 'idiopathic', is actually a meticulous bouncer at the lung's exclusive club, letting in a varied guest list of genetic VIPs, blue-collar occupations, smokers, and even the occasional aspirated stomach acid, while curiously turning away the obese.
Sources & References
- Reference 1ATSJOURNALSatsjournals.orgVisit source
- Reference 2ERJerj.ersjournals.comVisit source
- Reference 3NCBIncbi.nlm.nih.govVisit source
- Reference 4THORAXthorax.bmj.comVisit source
- Reference 5MYmy.clevelandclinic.orgVisit source
- Reference 6RESMEDJOURNALresmedjournal.comVisit source
- Reference 7CDCcdc.govVisit source
- Reference 8FRONTIERSINfrontiersin.orgVisit source
- Reference 9PULMONARYFIBROSISpulmonaryfibrosis.orgVisit source
- Reference 10MJAmja.com.auVisit source
- Reference 11ERSNETersnet.orgVisit source
- Reference 12NATUREnature.comVisit source
- Reference 13NEJMnejm.orgVisit source
- Reference 14MAYOCLINICmayoclinic.orgVisit source